Amgen Inc. (BVMF:AMGN34)

Market Cap	839.63B
Revenue (ttm)	190.26B
Net Income (ttm)	36.07B
Shares Out	n/a
EPS (ttm)	66.64
PE Ratio	23.28
Forward PE	14.05
Dividend	1.29 (2.32%)
Ex-Dividend Date	May 15, 2025

Volume	1
Average Volume	86
Open	55.50
Previous Close	55.50
Day's Range	55.50 - 55.50
52-Week Range	52.50 - 75.12
Beta	0.48
RSI	35.85
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: AMGN34

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD